CCG Policy for Working with the Pharmaceutical Industry

Size: px
Start display at page:

Download "CCG Policy for Working with the Pharmaceutical Industry"

Transcription

1 CCG Policy for Working with the Pharmaceutical Industry 1. Introduction Medicines are the most frequently and widely used NHS treatment and account for over 12% of NHS expenditure. The Pharmaceutical Industry has always worked closely with the NHS, clinicians and commissioning organisations. The establishment of Clinical Commissioning Groups puts clinicians at the centre of commissioning to deliver excellent healthcare by building effective and appropriate working relationships with key partners such as the pharmaceutical industry. This means that there is even greater complexity in relation to what could be deemed conflict of interest. It is essential that there are clear procedures for the CCG staff and members and supporting individuals and organisations (including private and voluntary) where there may be potential for a conflict of interest that could affect commissioning decisions related to medicines and associated services. CCG staff and members should be aware that industry representatives must follow the ABPI Code of Practice for the Pharmaceutical Industry. Link to the 2015 version 5-NOV14_WEB.pdf It is a condition of membership of the Association of the British Pharmaceutical Industry (ABPI). The Code of Practice for the pharmaceutical industry is designed to ensure a professional, responsible and ethical approach to the promotion of prescription medicines in the UK through a self-regulatory system. If CCG staff or members believe that an industry representative has broken the Code, they should contact the CCG Lead pharmacist for information and advice, they will oversee any complaints being reported. CCG staff and members and private provider staff involved in NHS business should be aware that the nature of marketing and therefore pharmaceutical marketing means that decision making can be influenced in ways where the target audience may be unaware of being subject to influence. Therefore staff should maintain awareness and accept that this is possible and even probable. This is why full declarations of interests that are open to public scrutiny are important enabling greater objectivity. 2. Aims and Objectives of the Policy The aim of this policy is: To provide the CCG Governing Body with assurance that decisions made on medicines and medicines management in relation to pharmaceutical industry sponsorship, which give mutual advantage, are made within a framework of probity. To make clear to CCG employees, independent contractors and their staff the relevant principles, process and procedures to follow regarding business conduct Page 1 of 15

2 and accountability in relation to commercial sponsorship and dealings with the Pharmaceutical Industry (PI). To safeguard the interests of the CCG and reassure the public. To establish ways that the CCG can work constructively with the pharmaceutical industry. This policy should be read in conjunction with local CCG Standards of Business Conduct Policy and the CCG Anti-Fraud, Bribery and Corruption policies. This policy covers CCG employees, independent contractors and their staff in the course of NHS business. The CCG requests that member practices also adhere to the principles outlined within it. 3. Declarations of interest and Hospitality Register The CCG must maintain registers of interest in relation to the CCG staff and membership. Conflicts might occur due to the possibility of individuals having: A direct financial interest An indirect financial interest Non-financial or personal interests Conflicts of loyalty. The CCG is also required to maintain a register of any hospitality provided or offered to any staff member in the course of carrying out CCG duties. Please refer to local Standards of Business Conduct policy regarding declarations of interests and hospitality register. 4. Attendance at Sponsored Clinical Training or Education Meetings CCG staff and membership should ensure there is an entry made on the CCG hospitality register regarding any clinical training or education provided by or sponsored by a pharmaceutical company. This should include details of company name, drugs discussed at meetings, and hospitality or other sponsorship provided. The CCG hospitality register will be available for CCG and public scrutiny. CCG member practices - it is recommended that each practice should maintain a register of dealings with the Pharmaceutical Industry including any clinical training or education provided or sponsored by a pharmaceutical company. This should include details of company name, drugs discussed at meetings, and hospitality or other sponsorship provided. The Practice Register of Interests should be available for CCG and public scrutiny. 5. Meetings with Pharmaceutical Company Representatives The CCG does not approve any cold calling to CCG employees, independent contractors and their staff from PI representatives. Page 2 of 15

3 All requests for meetings and contacts by PI representatives to staff, or the membership should be undertaken using the dedicated proforma (See Appendix 1). All contact should then be via to a generic address until such a decision has been made that a meeting will take place. In considering requests for meetings with representatives of the PI, consideration should be given to whether this will represent best use of CCG staff or member s time and therefore not all requests can be granted. Details should be forwarded to the CCG lead pharmacist via following any PI meetings for maintenance of a register of meetings which will be available for public scrutiny. GP and any other clinician members of the CCG who PI representatives may contact in their capacity as prescribers or related health professionals should follow good practice and ensure representatives complete a similar form prior to meeting, for inclusion in the practice register of dealings with the pharmaceutical Industry. The register should include details of the meeting, date, representative and company name, practice members present, drugs and services discussed, hospitality received. This register should be available for CCG and public scrutiny. Members of the CCG considering meeting with PI representatives in their capacity as clinicians at practice level should also consider whether this will represent good use of their time given the arrangements in place locally through CCG and Area Prescribing Committee for recommendations on new drugs, formulary, and guidelines and on medicines safety. 6. Sponsorship of Meetings Sponsorship of meetings is not permitted for routine internal meetings of the CCG. Sponsorship may be obtained only for educational or special events. The ABPI Code states that meetings must be held in appropriate venues conducive to the main purpose of the event. Hospitality must be strictly limited to the main purpose of the event and must be secondary to the purpose of the meeting i.e. subsistence only. The level of subsistence offered must be appropriate and not out of proportion to the occasion. The costs involved must not exceed that level which the recipients would normally adopt when paying for themselves. It must not extend beyond members of the health professions or appropriate administrative staff. For sponsored meetings being organised by staff or CCG members (other than for their own GP practice), a form for proposed sponsorship of meeting must be completed and forwarded to the Lead Pharmacist so that an overview of sponsorship of meetings by the CCG can be maintained and details can be held as a register of sponsorship of meetings available for public scrutiny. This form is attached in appendix 2. When seeking sponsorship for a meeting, use of a company with products directly related to the topic under consideration should be avoided as far as possible. Please Page 3 of 15

4 contact the lead pharmacist for advice if you are unsure. Products that are not approved by the CCG or the Pan Mersey APC formulary should not be promoted. If meetings are sponsored by pharmaceutical companies, that fact must be disclosed in all of the papers relating to the meetings and in any published proceedings. The declaration of sponsorship must be sufficiently prominent to ensure that readers are aware of it at the outset. Details of the sponsorship should also be highlighted to attendees at the beginning of the meeting. For PI sponsored meetings, the level of access to clinicians or associated staff for the promotion of specific drugs or services by the pharmaceutical company (before the primary purpose of the meeting commences) must be agreed in advance, (as stated on sponsorship request form). For a sponsored sandwich lunch for example the representative could have a stand with promotional materials and attend the stand to engage with attendees during lunch and before the meeting starts. Representative/s of the pharmaceutical company sponsoring the meeting should be thanked for the sponsorship ahead of the commencement of the primary purpose of the meeting and then must not remain in attendance at the meeting unless it is a public meeting. For CCG members obtaining sponsorship for practice meetings details of the sponsorship must be kept in a practice register of dealings with the pharmaceutical industry, which should be available for CCG and public scrutiny. Meetings of the Governing Body The CCG holds meetings of its Governing Body in public and is required to do so both by statute and its Constitution. They are often attended by representatives of pharmaceutical companies. Those representatives attend meetings in their capacity as members of the public and have no special privileges when they do so. They should receive no greater or lesser opportunity to participate in the meeting or engage with individual members of the Governing Body than would any other member of the public. Members of the Governing Body may be approached by representatives who seek to engage with them for the purpose of promoting their particular products or canvassing support for products or projects. It is recommended that they politely but firmly decline to engage with pharmaceutical representatives in these circumstances. 7. Joint working with Pharmaceutical Companies For the purpose of this policy joint working is defined as situations where, for the benefit of patients, the CCG and one or more pharmaceutical companies pool skills, experience and/or resources for the joint development and implementation of patient centered projects and share a commitment to successful delivery. Joint working agreements and management arrangements are conducted in an open and transparent manner. Joint working differs from sponsorship, where pharmaceutical companies simply provide funds for a specific event or work programme. Page 4 of 15

5 Joint working between the pharmaceutical industry and the CCG must be for the benefit of patients or the NHS and preserve patient care; the main beneficiary being the patient. Joint working arrangements must be entered into at a corporate level and not with any individual member of staff or CCG member practice. Any tentative discussion about entering into joint working which staff or CCG members may have and consider worth pursuing should first be discussed with their line manager and the Lead Pharmacist and as appropriate brought to the attention of the Chief Officer. If the proposal is deemed suitable to explore further the designated lead should provide initial details on the joint working outline proposal using the quality standards checklist for considering commercial partnerships and this should be submitted to the Lead Pharmacist for consideration. (see appendix 3) If the initial outline is supported by the Quality/Standards Committee and the Medicines Management Committee a project group should be established to produce a full proposal for consideration by the CCG Board. The length of the arrangement, the potential implications for patients and the NHS, together with the perceived benefits for all parties, should be clearly outlined before entering into any joint working. When entering into an agreement for joint working, the CCG must also consider the impact once these arrangements are concluded. An effective exit strategy must be in place at the outset of a given project detailing the responsibilities of each party. A formal written agreement must be in place and an executive summary of the joint working agreement must be made publicly available before arrangements are implemented. All aspects of confidentiality with regard to patient information must be observed and how this will be achieved clearly stated in the Joint Working Agreement. Confidentiality of information received in the course of duty should be respected and should never be used outside the scope of the specific exercise. Arrangements for monitoring the operation of the agreement and assessing clinical and financial outcomes should be agreed and clearly stated within the Joint Working Agreement. All assessments of the joint working programme should be made readily available to other NHS organisations and the public. 8. Primary Care Pharmaceutical Rebate Schemes Primary care rebate schemes (PCRS) are contractual arrangements offered by pharmaceutical companies, or third party companies, which offer financial rebates on GP prescribing expenditure for particular branded medicine(s). Such schemes are increasingly being offered to Clinical Commissioning Groups (CCGs) by the pharmaceutical industry as a means to introduce new drugs into the NHS, or more simply as a tool to increase/ establish market share of existing or new medicine(s). Page 5 of 15

6 This policy provides the clarity and guidance for the CCG when considering entering in a primary care rebate scheme. Rebate schemes are different from national patient access schemes, which are recognised by NHS England to manage entry of new products to the market at a reduced cost. However both approaches serve to protect the list price of the product, which is used as a reference by markets in other countries. The London Primary Care Medicines Use and Procurement (LPP) group have reviewed such schemes and following legal and stakeholder consultation, have set out principles of good practice for use by CCGs, to facilitate robust scrutiny of rebate schemes. The document acknowledges the disparity of whether these schemes are allowed within current regulations, acknowledging the concern that proliferation of primary care rebate schemes may cause an unacceptable administrative burden to the NHS. To help to manage concerns, LPP obtained legal advice and are satisfied that the schemes are not unlawful but do need to meet certain requirements to avoid falling foul not only of the Drug Tariff and the controls on pricing under the NHS Act 2006, but of a raft of other UK legislation including the Medicines Act, Human Medicines Regulations, the Bribery Act and EU laws. Any rebate scheme must be compatible with the effective, efficient and economic use of NHS resources. The CCG will adhere to the principles of good practice when deciding whether it participates in a PCRS or not these principles are set out in the LPP check list (appendix 4) The Pharmaceutical Industry Scheme Governance Review Board of PresQIPP (an organisation hosted and funded by NHS England to support quality optimized medicines management within the NHS) will assess any rebate scheme for clinical, financial and contractual issues to support CCGs in addressing the risk of perverse incentives from Rebate schemes. Previous assessments are saved on the website for CCGs to consider. Any rebates offered to the CCG will be considered in full by the Medicines Management Committee and any decisions will be ratified by the Quality committee and Finance Committee. Note This policy has been reproduced with kind permission from a document prepared by the Medicines Management Lead for Halton CCG Page 6 of 15

7 Appendix 1. Appointment Request Form for Representatives from the Pharmaceutical Industry Request Date All sections must be completed prior to consideration of an appointment Please to the appropriate address detailed on overleaf Name of Representative Name of Company /Mobile No. (NB we may offer teleconference appointments) Category of topic(s) you wish to discuss Please mark the relevant category/categories CCG commissioning pathways and service development Prescribing please complete additional table below for any requests relating to prescribing Proposed joint working ALL requests relating to prescribing please complete (highlight all relevant) Please mark the relevant category/categories New Medicine Formulary Sharing Resources Clinical data (efficacy, safety etc) Licence extension Medicines optimisation collaborative initiative Budget impact document New formulation of existing medicine Other collaborative initiative Pre-licence advanced planning notification Efficiency saving Outline what you wish to discuss and attach relevant pre-reading material What is the outcome you hope to achieve from the meeting? How long do you anticipate the meeting lasting? Page 7 of 15

8 Office Use Only Date of last appointment To be given an appointment Yes No Urgent Routine If no appointment given give a brief explanation for the reason Appointment details appointment Duration 15 mins 30 mins Other (specify).. 45 mins 60 mins Date Venue (give full address and post code) Time Please the completed for to the following address: CCG commissioning and service development please - Insert CCG contact Requests to discuss prescribing please Insert CCG contact Please note any requests to discuss prescribing not sent to the correct address will not be responded to. Page 8 of 15

9 Appendix 2. Request proforma (CCG internal) for sponsorship of a meeting by a pharmaceutical company CCG Lead or member of staff organising the meeting: Title and details of Meeting: Target audience: Venue: Proposed date: Proposed Pharmaceutical Company: Representative name and contact details: Details of sponsorship requested: Approximate value of sponsorship: Details of direct marketing contact at meeting: e.g. whether representative will attend the meeting, have a marketing stand showing product information; which products and or services will be marketed. Please forward the completed form to the CCG Lead Pharmacist for recording on the Pharmaceutical company register of sponsorship Page 9 of 15

10 Appendix 3 Quality Standards Checklist for considering Joint Working with a commercial company or the pharmaceutical industry (Adapted from Harrogate and Rural District CCG policy) Quality Standards Checklist for considering Joint Working with a commercial company or the pharmaceutical industry Is the company or organisation legitimate that is, is it a registered company capable of being independently audited? Does the scheme have aims and objectives? Yes No Does the sponsorship offer any benefits to the following aspects of health care? a) Diagnostic and referral? b) Investigations and measurements? c) Informing and educating patients? Is the material non-promotional accurate and culturally appropriate? Will the material be checked by the CCG before it is distributed? d) Informing and educating health professionals? Is the information valid, complete, balanced and up to date? Sponsorship that is directly related to patient treatment a) Is the sponsorship related to patient treatment? b) Have alternative treatments been considered and evaluated? c) Has an assessment of the costs and benefits of the package in relation to alternative options been investigated? d) Has monitoring of the patients been considered as part of the treatment? e) Has a criteria for success of the project been established? f) Has patient perceptions been included as part of the criteria? g) Has a health care professional been designated clinically responsible for the patient at each stage of the package? h) Has an assessment been made as to how the package fits with existing systems of primary and secondary care? Information/data considerations a) Is the sponsorship related to the collection of data? Page 10 of 15

11 b) Who will own the data? Please state: c) Will the sponsor have access to the data? d) Have the provisions of the Data Protection Act been taken into consideration? e) Who will evaluate the data? Please state: Sponsorship related to the provision of products Is the sponsorship related to any of the following? a) Provision of clinical products? Will this encourage the use of a particular product in the future? Will the use of the product limit patient choice? b) Provision of equipment? Is the equipment linked to the use of one particular brand of consumables? Has an assessment been undertaken to establish that it is the best for purpose? c) Provision of free stationery? Does the stationery include commercial advertising? Has the CCG control over the content of the advertising? Are there any recurring costs for the scheme? Who will be responsible for recurring costs? Please state Further Information Page 11 of 15

12 Appendix 4 Primary Care Rebate Scheme Checklist Developed from the London Primary Care Medicines Use and Procurement (LPP) group checklist Date: Name of Drug: Company Name: Company Contact: CCG Checklist for Primary Care Rebate Schemes Issue Good practice principles Comments 1. Product-related 1.1 Before any consideration of price, the clinical need for the medicine and its place in care pathways should have been agreed by established local decision-making processes. The clinical decision should inform the financial/procurement decision and not vice versa. 1.2 Health professionals should always base their prescribing decisions primarily on assessments of their individual patients clinical circumstances. The impact of a rebate scheme is a secondary consideration. 1.3 Any medicine considered under a PCRS must be licensed in the UK. Where there is more than one licensed indication for a medicine, a scheme should not be linked to a particular indication for use. 1.4 Rebate schemes promoting unlicensed or off label uses must not be entered into. All recommendations for use of a medicine within a PCRS must be consistent with the Marketing Authorisation of the medicine in question i.e. the PCRS should only advocate the use of the drug in line with the data sheet for the drug in question. Page 12 of 15

13 2. Rebate schemerelated 1.5 Medicines not recommended by NICE might still be the subject of a PCRS, but specific and documented consideration must be given to how such a product can properly be recommended to prescribers notwithstanding NICE s position. CCGs will need to explain how the scheme helps it meet its duty to use its resources effectively, efficiently and economically. 2.1 Decision making processes should be clinically-led and involve all appropriate stakeholders, including patients where appropriate. 2.2 Rebate schemes should be approved through robust local governance processes that include Medicines Management Working Group and Quality Committee approval 2.3 The administrative burden to the NHS of setting up and running the scheme must be factored into assessment of likely financial benefit of the scheme. Consideration should be given to audit requirements, financial governance, data collection, any other hidden costs and practical issues such as the term of agreement. 2.4 Primary care rebate schemes should be agreed at a statutory organisational level, they should not be agreed at GP practice level. 2.5 Schemes encouraging exclusive use of a particular drug should be avoided. 2.6 Rebate schemes for medicines in Category M and some medicines in Category C of the Drug Tariff, should be especially carefully considered because of the potential wider impact on community pharmacy reimbursement. Short term local savings are likely to be offset by increased costs to the wider NHS in the longer term. Schemes which promote prescribing of branded generics or original brands in preference to generics pose the added risk that they undermine the concept of generic prescribing. 2.7 The PCRS should not be directly linked to requirements to increase market share or volume of prescribing. 2.8 Schemes which link a rebate directly to increase in volume of prescribing above a defined threshold could be judged to be an attempt to influence prescribing inappropriately and should be avoided. Page 13 of 15

14 2.9 Commissioners should ensure that a formal written contract is in place, signed by both parties to ensure (i) that the terms of the scheme are clear and (ii) to maximise the legal protection. All negotiations around a scheme should be expressed as being "subject to contract" i.e. not binding until the formal contract has been signed by both parties PCRS agreements should include a right to terminate on notice (i.e., without having to have any reason for doing so) with a sensible notice period e.g. three or six months. 3. Information and Transparency 2.11 The need for exit criteria and an exit strategy should be considered before a scheme is agreed. It is essential to allow flexibility to respond to emergence of significant new clinical evidence, or significant changes in market conditions. A shorter notice period should be agreed in these circumstances Is the value of the offer quantifiable and proportionate to the administrative burden? Is there an appropriate return on investment? 2.13 Schemes which link a rebate to prescribing of more than one drug should be especially carefully considered to avoid the risk that savings made on one are indirectly offset by costs incurred on another. 3.1 The CCG will make public the existence of any PCRS they have agreed to. 3.2 The CCG will not enter into any PCRS which precludes them from considering any other schemes subsequently offered by manufacturers of competitor drugs, should they wish to do so. 3.3 There should be no requirement to collect or submit to the manufacturer any data other than volume of use as derived from epact data. 3.4 PCRS agreements must meet the requirements of the Data Protection Act and patient confidentiality must never be compromised. 3.5 The CCG will not enter schemes that require them to provide information to a manufacturer about competitor products market share. Page 14 of 15

15 3.6 Freedom of Information provisions about FOI requests and commercially sensitive information should be contained in the contract. As a general principle, information about rebate schemes may be released under FOI requests, but commercially sensitive information is usually withheld. 3.7 Discounts and details of any PCRS offered should be allowed to be shared within the NHS. This should be agreed as part of the PCRS contract. 3.8 Is the invoicing process transparent as per NHS financial requirements? Page 15 of 15

WORKING WITH THE PHARMACEUTICAL INDUSTRY POLICY Version 1.0

WORKING WITH THE PHARMACEUTICAL INDUSTRY POLICY Version 1.0 WORKING WITH THE PHARMACEUTICAL INDUSTRY POLICY Version 1.0 1 Standard Operating Procedure St Helens CCG Working with The Pharmaceutical Industry Policy Version 1.0 Implementation Date May 2017 Review

More information

SPONSORSHIP AND JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY

SPONSORSHIP AND JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY SPONSORSHIP AND JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY 1 SUMMARY This document sets out Haringey Clinical Commissioning Group policy and advice to employees on sponsorship and joint working with

More information

Policy for the Sponsorship of Activities and Joint Working with the Pharmaceutical Industry

Policy for the Sponsorship of Activities and Joint Working with the Pharmaceutical Industry Policy for the Sponsorship of Activities and Joint Working with the Pharmaceutical Industry March 2017 NOTE: This policy will be subject to review in 2017/18 as part of the partnership work between North

More information

WORKING WITH THE PHARMACEUTICAL INDUSTRY

WORKING WITH THE PHARMACEUTICAL INDUSTRY WORKING WITH THE PHARMACEUTICAL INDUSTRY Page 1 of 11 WORKING WITH THE PHARMACEUTICAL INDUSTRY CCG Policy Reference: SuttonCCG/SLCSU/GOV/099 THIS POLICY WILL BE APPROVED BY THE CLINICAL COMMISSIONING GROUP

More information

Version 1.0. Quality, Performance & Finance. Date Ratified 31 st March 2015 Iain Stewart, Head of Direct Commissioning

Version 1.0. Quality, Performance & Finance. Date Ratified 31 st March 2015 Iain Stewart, Head of Direct Commissioning Joint working with the pharmaceutical industry Policy (Template based upon DH Best Practice Guidance for Joint Working between the NHS and the Pharmaceutical Industry, February 2008) Version 1.0 Ratified

More information

Guidance For Health Care Staff Within NHS Grampian On Working With The Pharmaceutical Industry And Suppliers Of Prescribable Health Care Products

Guidance For Health Care Staff Within NHS Grampian On Working With The Pharmaceutical Industry And Suppliers Of Prescribable Health Care Products Title: Identifier: Guidance For Health Care Staff Within NHS Grampian On Working With The Pharmaceutical Industry And Suppliers Of Prescribable Health Care Products NHSG/guid/PharmInd/GMMG/738 Replaces:

More information

MEDICINES STANDARD B3: WORKING WITH THE PHARMACEUTICAL INDUSTRY

MEDICINES STANDARD B3: WORKING WITH THE PHARMACEUTICAL INDUSTRY MEDICINES STANDARD B3: WORKING WITH THE PHARMACEUTICAL INDUSTRY NHS employees and contractors link with the pharmaceutical industry in a number of ways, as a source of information, through the receipt

More information

Transparency and doctors with competing interests guidance from the BMA

Transparency and doctors with competing interests guidance from the BMA Transparency and doctors with competing interests British Medical Association bma.org.uk British Medical Association Transparency and doctors with competing interests 1 Introduction The need for transparency

More information

NHS Fife WORKING WITH THE PHARMACEUTICAL INDUSTRY AND HEALTHCARE EQUIPMENT SUPPLIERS GUIDANCE FOR NHS STAFF

NHS Fife WORKING WITH THE PHARMACEUTICAL INDUSTRY AND HEALTHCARE EQUIPMENT SUPPLIERS GUIDANCE FOR NHS STAFF NHS Fife WORKING WITH THE PHARMACEUTICAL INDUSTRY AND HEALTHCARE EQUIPMENT SUPPLIERS GUIDANCE FOR NHS STAFF This guidance relates to all staff employed by NHS Fife (including staff within the Health &

More information

Commercial Sponsorship and Joint Working with the Pharmaceutical Industry Policy

Commercial Sponsorship and Joint Working with the Pharmaceutical Industry Policy Commercial Sponsorship and Joint Working with the Pharmaceutical Industry Policy Ratified Status Approved Final Issued November 2017 Approved By Consultation Governance and Risk Committee CCG Head of Governance

More information

POLICY FOR SPONSORSHIP OF ACTIVITIES, JOINT WORKING AND TRAINING AND EDUCATION BY THE PHARMACEUTICAL INDUSTRY WITH

POLICY FOR SPONSORSHIP OF ACTIVITIES, JOINT WORKING AND TRAINING AND EDUCATION BY THE PHARMACEUTICAL INDUSTRY WITH POLICY FOR SPONSORSHIP OF ACTIVITIES, JOINT WORKING AND TRAINING AND EDUCATION BY THE PHARMACEUTICAL INDUSTRY WITH NOTTINGHAMSHIRE CLINICAL COMMISSIONING GROUPS Contents 1. Background... 3 2. Purpose of

More information

P10 Working with the Pharmaceutical Industry

P10 Working with the Pharmaceutical Industry Working with the Pharmaceutical Industry Policy: P10 Policy Descriptor This document is intended to serve as a guide to Devon Partnership NHS Trust staff and the Trust as a whole with regard to interacting

More information

POLICY ON JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY. Issued by: Director of Quality, Governance and Patient Safety

POLICY ON JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY. Issued by: Director of Quality, Governance and Patient Safety POLICY ON JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY Issued by: Director of Quality, Governance and Patient Safety Policy Classification: Corporate Issue No: 001 Page No: 1 of 19 Policy No. POLCP007

More information

Policy on Sponsorship and Joint Working with the Pharmaceutical Industry and other Commercial Organisations

Policy on Sponsorship and Joint Working with the Pharmaceutical Industry and other Commercial Organisations Policy on Sponsorship and Joint Working with the Pharmaceutical Industry and other Commercial Organisations Author: Melanie Preston, Assistant Director of Medicines Optimisation Blackpool CCG & Louise

More information

Version Number Date Issued Review Date V1 July /08/2015 July 2017

Version Number Date Issued Review Date V1 July /08/2015 July 2017 Corporate CCG CO23 Commercial Sponsorship and Joint Working with the Pharmaceutical Industry Policy Version Number Date Issued Review Date V1 July 2015 13/08/2015 July 2017 Prepared By: Consultation Process:

More information

Corporate/General Finance

Corporate/General Finance Document title: Policy and Guidance for Joint Working with the Pharmaceutical Industry (including rebate schemes) & Commercial Sponsorship of Meetings/Training Events CCG document ref: Author / originator:

More information

How NICE clinical guidelines are developed

How NICE clinical guidelines are developed Issue date: January 2009 How NICE clinical guidelines are developed: an overview for stakeholders, the public and the NHS Fourth edition : an overview for stakeholders, the public and the NHS Fourth edition

More information

Process and methods Published: 23 January 2017 nice.org.uk/process/pmg31

Process and methods Published: 23 January 2017 nice.org.uk/process/pmg31 Evidence summaries: process guide Process and methods Published: 23 January 2017 nice.org.uk/process/pmg31 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

Standards conduct, accountability

Standards conduct, accountability Standards of conduct, accountability and openness Standards of conduct, accountability and openness Throughout this document: members refers to all members of a board the Chair, the non-executives, the

More information

Commercial Sponsorship and Joint Working with the Pharmaceutical Industry Policy November 2017

Commercial Sponsorship and Joint Working with the Pharmaceutical Industry Policy November 2017 Commercial Sponsorship and Joint Working with the Pharmaceutical Industry Policy November 2017 Authorship: Medicines Optimisation Team North of England Commissioning Support Committee Approved: Quality

More information

ABPI Guidance Notes on Joint Working between Pharmaceutical Companies and the NHS and Others for the Benefit of Patients

ABPI Guidance Notes on Joint Working between Pharmaceutical Companies and the NHS and Others for the Benefit of Patients ABPI Guidance Notes on Joint Working between Pharmaceutical Companies and the NHS and Others for the Benefit of Patients Taking into Consideration the 2008 ABPI Code of Practice for the Pharmaceutical

More information

Policy on Sponsorship and Joint Working with the Pharmaceutical Industry and other Commercial Organisations

Policy on Sponsorship and Joint Working with the Pharmaceutical Industry and other Commercial Organisations Policy on Sponsorship and Joint Working with the Pharmaceutical Industry and other Commercial Organisations Page 1 of 23 DOCUMENT CONTROL Policy Title: Purpose: Supersedes: This policy applies to: Circulation:

More information

Reservation of Powers to the Board & Delegation of Powers

Reservation of Powers to the Board & Delegation of Powers Reservation of Powers to the Board & Delegation of Powers Status: Draft Next Review Date: March 2014 Page 1 of 102 Reservation of Powers to the Board & Delegation of Powers Issue Date: 5 April 2013 Document

More information

NHS WOLVERHAMPTON CLINICAL COMMISSIONING GROUP CONSTITUTION

NHS WOLVERHAMPTON CLINICAL COMMISSIONING GROUP CONSTITUTION NHS WOLVERHAMPTON CLINICAL COMMISSIONING GROUP CONSTITUTION Version: [78] NHS England Effective Date: 1 December 2015 April 2017 CONTENTS Part Description Page Foreword 1 1 Introduction and Commencement

More information

NHS GREATER GLASGOW AND CLYDE POLICIES RELATING TO THE MANAGEMENT OF MEDICINES SECTION 9.1: UNLICENSED MEDICINES POLICY (ACUTE DIVISION)

NHS GREATER GLASGOW AND CLYDE POLICIES RELATING TO THE MANAGEMENT OF MEDICINES SECTION 9.1: UNLICENSED MEDICINES POLICY (ACUTE DIVISION) SECTION 9.1: UNLICENSED MEDICINES POLICY (ACUTE DIVISION) CONTENTS POLICY SUMMARY... 2 1. SCOPE... 4 2. AIM... 4 3. BACKGROUND... 4 4. POLICY STATEMENTS... 5 4.1. GENERAL STATEMENTS... 5 4.2 UNLICENSED

More information

COMMISSIONING SUPPORT PROGRAMME. Standard operating procedure

COMMISSIONING SUPPORT PROGRAMME. Standard operating procedure NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE COMMISSIONING SUPPORT PROGRAMME Standard operating procedure April 2018 1. Introduction The Commissioning Support Programme (CSP) at NICE supports the

More information

NHS. The guideline development process: an overview for stakeholders, the public and the NHS. National Institute for Health and Clinical Excellence

NHS. The guideline development process: an overview for stakeholders, the public and the NHS. National Institute for Health and Clinical Excellence NHS National Institute for Health and Clinical Excellence Issue date: April 2007 The guideline development process: an overview for stakeholders, the public and the NHS Third edition The guideline development

More information

CODE OF CONDUCT CODE OF ACCOUNTABILITY IN THE NHS

CODE OF CONDUCT CODE OF ACCOUNTABILITY IN THE NHS CODE OF CONDUCT CODE OF ACCOUNTABILITY IN THE NHS CODE OF CONDUCT Public Service Values General Principles Openness and Public Responsibilities Public Service Values in Management Public Business and Private

More information

Version Number Date Issued Review Date V2 September 2017 September Helen Seymour, Senior Medicines Optimisation Pharmacist, NECS

Version Number Date Issued Review Date V2 September 2017 September Helen Seymour, Senior Medicines Optimisation Pharmacist, NECS Corporate CO23: Commercial sponsorship and joint working with the pharmaceutical industry Version Number Date Issued Review Date V2 September 2017 September 2019 Prepared By: Reviewed By: Consultation

More information

Prescribing Policy between Nottinghamshire Commissioning Organisations and local providers of NHS Services

Prescribing Policy between Nottinghamshire Commissioning Organisations and local providers of NHS Services Prescribing Policy between Nottinghamshire Commissioning Organisations and local providers of NHS Services Document Purpose Version 2.2 To detail the specific contractual issues associated with prescribing

More information

Guidelines for Pharmacists Relationship with the Pharmaceutical Industry

Guidelines for Pharmacists Relationship with the Pharmaceutical Industry Guidelines for Pharmacists Relationship with the Pharmaceutical Industry July 2002 These guidelines represent general advice to support and assist pharmacists. It is expected that professional judgement

More information

Methods: Commissioning through Evaluation

Methods: Commissioning through Evaluation Methods: Commissioning through Evaluation NHS England INFORMATION READER BOX Directorate Medical Operations and Information Specialised Commissioning Nursing Trans. & Corp. Ops. Commissioning Strategy

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health and Social Care Directorate Quality standards Process guide

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health and Social Care Directorate Quality standards Process guide NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health and Social Care Directorate Quality standards Process guide December 2014 Quality standards process guide Page 1 of 44 About this guide This guide

More information

Central Alerting System (CAS) Policy

Central Alerting System (CAS) Policy Document Title Reference Number Lead Officer Author(s) (name and designation) Ratified By Central Alerting System (CAS) Policy NTW(O)17 Gary O Hare Executive Director of Nursing and Operations Tony Gray

More information

South East London Interface Prescribing Policy including the NHS and Private Interface Prescribing Guide

South East London Interface Prescribing Policy including the NHS and Private Interface Prescribing Guide South East London Interface Prescribing Policy including the NHS and Private Interface Prescribing Guide 1. Introduction 1.1 This policy has been developed by the South East London Clinical Commissioning

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Interim Process and Methods of the Highly Specialised Technologies Programme

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Interim Process and Methods of the Highly Specialised Technologies Programme NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Principles Interim Process and Methods of the Highly Specialised Technologies Programme 1. Our guidance production processes are based on key principles,

More information

ALLOCATION OF RESOURCES POLICY FOR CONTINUING HEALTHCARE FUNDED INDIVIDUALS

ALLOCATION OF RESOURCES POLICY FOR CONTINUING HEALTHCARE FUNDED INDIVIDUALS ALLOCATION OF RESOURCES POLICY FOR CONTINUING HEALTHCARE FUNDED INDIVIDUALS APPROVED BY: South Gloucestershire Clinical Commissioning Group Quality and Governance Committee DATE Date of Issue:- Version

More information

CCG authorisation: the role of medicines management

CCG authorisation: the role of medicines management May 2012 The NHS medicines bill for 2010 was 12.9 billion, of which secondary care costs accounted for 32%. Prescribing inflation in 2010 ran at 4.8% and it is estimated that around 14% of total CCG budgets

More information

CODE OF CONDUCT WHERE GP PRACTICES OR CONSORTIA ARE POTENTIAL PROVIDERS OF CCG COMMISISONED SERVICES

CODE OF CONDUCT WHERE GP PRACTICES OR CONSORTIA ARE POTENTIAL PROVIDERS OF CCG COMMISISONED SERVICES CODE OF CONDUCT WHERE GP PRACTICES OR CONSORTIA ARE POTENTIAL 1. Introduction PROVIDERS OF CCG COMMISISONED SERVICES 1.1. Managing potential conflicts of interest appropriately is needed to protect the

More information

PHARMACEUTICAL REPRESENTATIVE POLICY NOVEMBER This policy supersedes all previous policies for Medical Representatives

PHARMACEUTICAL REPRESENTATIVE POLICY NOVEMBER This policy supersedes all previous policies for Medical Representatives PHARMACEUTICAL REPRESENTATIVE POLICY VEMBER 2017 This policy supersedes all previous policies for Medical Representatives Policy title Pharmaceutical Representative Policy Policy PHA39 reference Policy

More information

The Newcastle upon Tyne Hospitals NHS Foundation Trust. Access to Drugs Policy

The Newcastle upon Tyne Hospitals NHS Foundation Trust. Access to Drugs Policy The Newcastle upon Tyne Hospitals NHS Foundation Trust Access to Drugs Policy Version No.: 3.0 Effective From: 25 January 2016 Expiry Date: 25 January 2019 Date Ratified: 4 November 2015 Ratified By: Medicines

More information

Consultation on initial education and training standards for pharmacy technicians. December 2016

Consultation on initial education and training standards for pharmacy technicians. December 2016 Consultation on initial education and training standards for pharmacy technicians December 2016 The text of this document (but not the logo and branding) may be reproduced free of charge in any format

More information

COMMUNITY DEVELOPMENT AND SUPPORT EXPENDITURE SCHEME GUIDELINES

COMMUNITY DEVELOPMENT AND SUPPORT EXPENDITURE SCHEME GUIDELINES COMMUNITY DEVELOPMENT AND SUPPORT EXPENDITURE SCHEME GUIDELINES November 2009 Gaming Machine Tax Act 2001 First published October 2007 Revised July 2008 Revised February 2009 Revised November 2009 CONTENTS

More information

Framework for managing performer concerns NHS (Performers Lists) (England) Regulations 2013

Framework for managing performer concerns NHS (Performers Lists) (England) Regulations 2013 Framework for managing performer concerns NHS (Performers Lists) (England) Regulations 2013 Information reader box NHS England INFORMATION READER BOX Directorate Medical Operations Patients and Information

More information

Any Qualified Provider: your questions answered

Any Qualified Provider: your questions answered Any Qualified Provider: your questions answered September 8, 2011 These answers cover a range of questions about the detail of Any Qualified Provider on integrated care, competition and procurement, liability

More information

Delegated Commissioning Updated following latest NHS England Guidance

Delegated Commissioning Updated following latest NHS England Guidance Delegated Commissioning Updated following latest NHS England Guidance 13th August 2015 Croydon, Kingston, Merton, Richmond, Sutton and Wandsworth NHS Clinical Commissioning Groups and NHS England (Direct

More information

NHS and LA Reforms Factsheet 5

NHS and LA Reforms Factsheet 5 NHS and LA Reforms Factsheet 5 Supply of medicines for public health commissioned services a factsheet for local authorities 1. Introduction As of April 2013, local authorities have responsibility for

More information

abcdefghijklmnopqrstu

abcdefghijklmnopqrstu Healthcare Policy and Strategy Directorate Quality Division Dear Colleague INTRODUCTION AND AVAILABILITY OF NEWLY LICENSED MEDICINES IN THE NHS IN SCOTLAND Dear Colleague This guidance sets out the policy

More information

consultation A European health service? The European Commission s proposals on cross-border healthcare Key questions for NHS organisations

consultation A European health service? The European Commission s proposals on cross-border healthcare Key questions for NHS organisations the voice of the NHS in Europe consultation AUGUST 2008 NO. 1 A European health service? Key questions for NHS organisations The draft proposals aim to clarify the rules around existing rights to get treatment

More information

The Newcastle Upon Tyne Hospitals NHS Foundation Trust. Unlicensed Medicines Policy

The Newcastle Upon Tyne Hospitals NHS Foundation Trust. Unlicensed Medicines Policy The Newcastle Upon Tyne Hospitals NHS Foundation Trust Unlicensed Medicines Policy Version.: 2.4 Effective From: 13 October 2016 Expiry Date: 13 October 2018 Date Ratified: 12 October 2016 Ratified By:

More information

A meeting of NHS Bromley CCG Governing Body 25 May 2017

A meeting of NHS Bromley CCG Governing Body 25 May 2017 South East London Sector A meeting of NHS Bromley CCG Governing Body 25 May 2017 ENCLOSURE 4 SOUTH EAST LONDON 111 AND GP OUT OF HOURS MEMORANDUM OF UNDERSTANDING SUMMARY: The NHS England Commissioning

More information

A fresh start for registration. Improving how we register providers of all health and adult social care services

A fresh start for registration. Improving how we register providers of all health and adult social care services A fresh start for registration Improving how we register providers of all health and adult social care services The Care Quality Commission is the independent regulator of health and adult social care

More information

Performance and Quality Committee

Performance and Quality Committee Title: NHS Continuing Health Care Choice Policy (addendum to Cornwall Wide Patient Choice, Equity and Fair Access Policy) Developed by: Document type: Policy library: NHS Kernow Policy Policies Sub Section:

More information

Medical Revalidation and Commercial Support for CPD Ian Starke. Medical Director, Revalidation, Royal College of Physicians. Licence to Practise Decide by 14 th August Issued November 2009 http://www.gmc-uk.org/doctors/licensing/faq/faq_licence_to_practise.asp

More information

COMMUNITY PHARMACY MINOR AILMENTS SERVICE

COMMUNITY PHARMACY MINOR AILMENTS SERVICE COMMUNITY PHARMACY MINOR AILMENTS SERVICE SUPPORTING SELF-CARE OCTOBER 2010 CONTENTS Index Page No 1 Introduction 3 2 Service Specification 4 3 Consultation Procedure 7 4 Re-ordering Documentation 10 Appendices

More information

Consultation on fee rates and fee scales

Consultation on fee rates and fee scales Consultation on fee rates and fee scales 2016-17 Consultation on fee rates and fee scales 2016-17 Overview This consultation invites views and comments on the Wales Audit Office s proposals for: fee rates

More information

Issue date: October Guide to the multiple technology appraisal process

Issue date: October Guide to the multiple technology appraisal process Issue date: October 2009 Guide to the multiple technology appraisal process Guide to the multiple technology appraisal process Issued: October 2009 This document is one of a series describing the processes

More information

3. Trustees and Governance 3.1 Charity and Clinical Governance

3. Trustees and Governance 3.1 Charity and Clinical Governance 3. Trustees and Governance 3.1 Charity and Clinical Governance This section outlines the governance responsibilities for air ambulances. The governance responsibilities and accountabilities for the NHS

More information

Consultation on developing our approach to regulating registered pharmacies

Consultation on developing our approach to regulating registered pharmacies Consultation on developing our approach to regulating registered pharmacies May 2018 The text of this document (but not the logo and branding) may be reproduced free of charge in any format or medium,

More information

Unlicensed Medicines Policy Document

Unlicensed Medicines Policy Document Unlicensed Medicines Policy Document Effective: February 2002 (Intranet 2006) Review date: February 2007 A. Introduction In order to ensure that medicines are safe and effective the manufacture and sale

More information

England. Questions and Answers. Draft Integrated Care Provider (ICP) Contract - consultation package

England. Questions and Answers. Draft Integrated Care Provider (ICP) Contract - consultation package England Questions and Answers Draft Integrated Care Provider (ICP) Contract - consultation package August 2018 Questions and Answers Draft Integrated Care Provider (ICP) Contract - consultation package

More information

All areas of the Trust All Trust staff All Patients Deputy Chief Nurse & Chief Pharmacist Final

All areas of the Trust All Trust staff All Patients Deputy Chief Nurse & Chief Pharmacist Final Trust Policy and Procedure Document Ref. No: PP(15)233 Non-Medical Prescribing Policy For use in: For use by: For use for: Document owner: Status: All areas of the Trust All Trust staff All Patients Deputy

More information

ADVOCATES CODE OF PRACTICE

ADVOCATES CODE OF PRACTICE ADVOCATES CODE OF PRACTICE Owner: Liz Fenton, Strategic Services Delivery Manager Approver: Management Team Date Document Version Draft/Final Distribution Comment 04/2006 1.0 Final All 12/2010 2.0 Final

More information

Corporate. Research Governance Policy. Document Control Summary

Corporate. Research Governance Policy. Document Control Summary Corporate Research Governance Policy Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation Date: Review Date:

More information

Daiichi Sankyo Group Global Marketing Code of Conduct

Daiichi Sankyo Group Global Marketing Code of Conduct Daiichi Sankyo Group Global Marketing Code of Conduct TABLE OF CONTENTS 1. PURPOSE... 3 2. SCOPE... 3 3. TERMS... 3 4. COMPLIANCE WITH LOCAL LAWS, REGULATIONS AND INDUSTRY CODES... 4 5. BASIS OF INTERACTIONS...

More information

Joint framework: Commissioning and regulating together

Joint framework: Commissioning and regulating together With support from NHS Clinical Commissioners Regulation of General Practice Programme Board Joint framework: Commissioning and regulating together A practical guide for staff January 2018 Publications

More information

5.3: POLICY FOR THE MANAGEMENT OF REQUESTS FOR MEDICINES VIA PEER APPROVED CLINICAL SYSTEM (PACS) TIER 2

5.3: POLICY FOR THE MANAGEMENT OF REQUESTS FOR MEDICINES VIA PEER APPROVED CLINICAL SYSTEM (PACS) TIER 2 NHS GREATER GLASGOW AND CLYDE POLICIES RELATING TO THE MANAGEMENT OF MEDICINES SECTION 5: NON-FORMULARY PROCESSES 5.3: POLICY FOR THE MANAGEMENT OF REQUESTS FOR MEDICINES VIA PEER APPROVED CLINICAL SYSTEM

More information

How to use NICE guidance to commission high-quality services

How to use NICE guidance to commission high-quality services How to use NICE guidance to commission high-quality services Acknowledgement We are grateful to the many organisations and individuals who have contributed to the development of this guide. A list of these

More information

Non Medical Prescribing Policy

Non Medical Prescribing Policy Non Medical Prescribing Policy Author: Sponsor/Executive: Responsible committee: Ratified by: Consultation & Approval: (Committee/Groups which signed off the policy, including date) This document replaces:

More information

A Case Review Process for NHS Trusts and Foundation Trusts

A Case Review Process for NHS Trusts and Foundation Trusts A Case Review Process for NHS Trusts and Foundation Trusts 1 1. Introduction The Francis Freedom to Speak Up review summarised the need for an independent case review system as a mechanism for external

More information

Birmingham CrossCity Clinical Commissioning Group Deprivation of Liberty Safeguards (DoLS) Policy: Supervisory body Functions

Birmingham CrossCity Clinical Commissioning Group Deprivation of Liberty Safeguards (DoLS) Policy: Supervisory body Functions Birmingham CrossCity Clinical Commissioning Group Deprivation of Liberty Safeguards (DoLS) Policy: Supervisory body Functions Policy Number Purpose of document To ensure that that the rights of patients

More information

Professional Practices Policy (P3)

Professional Practices Policy (P3) Novartis Global Policy Professional Practices Policy (P3) Novartis Global Policy March 1st, 2018 Version GIC 102.V1.EN NOVARTIS GLOBAL POLICY 2 Contents 1 Introduction... 3 2 Principles... 4 3 Policy...

More information

Dear Colleague. November 2013

Dear Colleague. November 2013 NHS Circular: PCA (P) (2013) 29 ehealth, Finance & Pharmaceutical Directorate Pharmacy & Medicines Division Dear Colleague ADDITIONAL PHARMACEUTICAL SERVICES INTRODUCTION OF GLUTEN FREE FOOD SERVICE TIMETABLE,

More information

Primary Care Commissioning Next Steps to Delegated Commissioning September Board Paper. 2.0 Delegated Opportunities, Benefits and Risks

Primary Care Commissioning Next Steps to Delegated Commissioning September Board Paper. 2.0 Delegated Opportunities, Benefits and Risks Primary Care Commissioning Next Steps to Delegated Commissioning September Board Paper 1.0 Introduction This paper provides a briefing to the Wandsworth CCG Board on our progress in developing a Primary

More information

1. Title of Paper: NHS Vale of York CCG Local Enhanced Services (LES) Review

1. Title of Paper: NHS Vale of York CCG Local Enhanced Services (LES) Review Item Number: 6 NHS VALE OF YORK CLINICAL COMMISSIONING GROUP GOVERNING BODY MEETING Meeting Date: 5 September 2013 Report Sponsor: Rachel Potts Chief Operating Officer Report Author: Melanie Cooper and

More information

COMIC RELIEF AWARDS THE GRANT TO YOU, SUBJECT TO YOUR COMPLYING WITH THE FOLLOWING CONDITIONS:

COMIC RELIEF AWARDS THE GRANT TO YOU, SUBJECT TO YOUR COMPLYING WITH THE FOLLOWING CONDITIONS: Example conditions of grant Below are the standard conditions that we ask grant holders to sign up to when accepting a grant from Comic Relief. These conditions are provided here only as an example; we

More information

Guidance on the provision of pharmacy services affected by religious and moral beliefs

Guidance on the provision of pharmacy services affected by religious and moral beliefs Guidance on the provision of pharmacy services affected by religious and moral beliefs September 2010 Guidance on the provision of pharmacy services affected by religious and moral beliefs The General

More information

Continuing Healthcare Policy

Continuing Healthcare Policy Continuing Healthcare Policy 1 SUMMARY This policy describes the way in which Haringey Clinical Commissioning Group (HCCG) will make provision for the care of people who have been assessed as eligible

More information

Unlicensed Medicines Policy

Unlicensed Medicines Policy Who Should Read This Policy Target Audience All Consultant/Senior Medical Staff All Junior Medical Staff All Non-Medical Prescribers All Pharmacy Staff All Nursing Staff Version 1.0 February 2016 Ref.

More information

OFFICIAL. Integrated Urgent Care Key Performance Indicators and Quality Standards Page 1 of 20

OFFICIAL. Integrated Urgent Care Key Performance Indicators and Quality Standards Page 1 of 20 Integrated Urgent Care Key Performance Indicators and Quality Standards 2018 Page 1 of 20 NHS England INFORMATION READER BOX Directorate Medical Operations and Information Specialised Commissioning Nursing

More information

NON-MEDICAL PRESCRIBING POLICY

NON-MEDICAL PRESCRIBING POLICY NON-MEDICAL PRESCRIBING POLICY To be read in conjunction with the Medicines Policy, Controlled Drug Policy and the FP10 Prescribing Forms Policy Version: 5 Date of issue: August 2017 Review date: August

More information

Draft NHS Standard Contract for 2015/16: a consultation

Draft NHS Standard Contract for 2015/16: a consultation Draft NHS Standard Contract for 2015/16: a consultation A response from Hospice UK 31 December 2014 1. About Hospice UK 1.1. Hospice UK (formerly Help the Hospices) is the national charity for hospice

More information

Wig and Hair Replacement Policy

Wig and Hair Replacement Policy Leeds CCGs Wigs and Hair Replacement Policy 2016-19 Wig and Hair Replacement Policy Version: 2016-19 Ratified by: NHS Leeds West CCG Assurance Committee on; 16 vember 2016 NHS Leeds rth CCG Governance

More information

ASSOCIATION FOR ACCESSIBLE MEDICINES Code of Business Ethics. March 2018

ASSOCIATION FOR ACCESSIBLE MEDICINES Code of Business Ethics. March 2018 ASSOCIATION FOR ACCESSIBLE MEDICINES Code of Business Ethics March 2018 Introduction Improving patient access to affordable medicines is a core value of companies that develop and manufacture generic and

More information

CONTINUING HEALTHCARE POLICY

CONTINUING HEALTHCARE POLICY BEFORE USING THIS POLICY ALWAYS ENSURE YOU ARE USING THE MOST UP TO DATE VERSION CONTINUING HEALTHCARE POLICY 1 SUMMARY This policy describes the way in which the five Primary Care Trusts in NHS North

More information

Community Child Care Fund - Restricted non-competitive grant opportunity (for specified services) Guidelines

Community Child Care Fund - Restricted non-competitive grant opportunity (for specified services) Guidelines Community Child Care Fund - Restricted non-competitive grant opportunity (for specified services) Guidelines Opening date: Closing date and time: Commonwealth policy entity: Co-Sponsoring Entities To be

More information

Papers for the. West Kent Primary Care Commissioning Committee (Improving Access) Tuesday 21 st August at 4 4:30 pm

Papers for the. West Kent Primary Care Commissioning Committee (Improving Access) Tuesday 21 st August at 4 4:30 pm Papers for the West Kent Primary Care Commissioning Committee (Improving Access) on Tuesday 21 st August at 4 4:30 pm at Hadlow Suite, Hadlow Manor Hotel Hadlow, TN11 0JH 1 of 23 Primary Care Commissioning

More information

Terms & Conditions of Award

Terms & Conditions of Award PART 1 1. INTRODUCTION 1 Terms & Conditions of Award 1.1. Part 1 of this Terms & Conditions of Award document sets out the standard terms and conditions for all British Academy awards. Additional terms

More information

Standards for Registered Pharmacies

Standards for Registered Pharmacies Council meeting 13 September 2012 Public business Standards for Registered Pharmacies Purpose This paper seeks the Council s approval of the standards for registered pharmacies. The Council is asked to

More information

NHS Rotherham CCG Medicines Management Team on behalf of NHS Rotherham CCG. Community Pharmacists in NHS Rotherham CCG

NHS Rotherham CCG Medicines Management Team on behalf of NHS Rotherham CCG. Community Pharmacists in NHS Rotherham CCG SERVICE LEVEL AGREEMENT TO ENABLE COMMUNITY PHARMACISTS IN NHS ROTHERHAM CLINICAL COMISSIONING GROUP TO SUPPLY TREATMENT AND ADVICE FOR MINOR AILMENTS PREPARED BY: NHS Rotherham CCG Medicines Management

More information

DRAFT - NHS CHC and Complex Care Commissioning Policy.

DRAFT - NHS CHC and Complex Care Commissioning Policy. DRAFT - NHS CHC and Complex Care Commissioning Policy. 1. Introduction 1.1 This policy describes the way the following Clinical Commissioning Groups (CCGs) NHS Wirral Clinical Commissioning Group, NHS

More information

The Mexico City Principles For Voluntary Codes of Business Ethics in the Biopharmaceutical Sector

The Mexico City Principles For Voluntary Codes of Business Ethics in the Biopharmaceutical Sector The Mexico City Principles For Voluntary Codes of Business Ethics in the Biopharmaceutical Sector E thical interactions help ensure that medical decisions are made in the best interests of patients. For

More information

Coastal West Sussex Interface Prescribing Policy

Coastal West Sussex Interface Prescribing Policy Coastal West Sussex Interface Prescribing Policy Agreement between Commissioners: Coastal West Sussex CCG And Providers: Western Sussex NHS Foundation Trust (WSfT) Sussex Community NHS Trust (SCT) Sussex

More information

Fair Processing Notice or Privacy Notice

Fair Processing Notice or Privacy Notice Fair Processing Notice or Privacy Notice What is a Fair Processing or Privacy notice? A privacy notice is an oral or written statement that individuals are given when information is collected about them.

More information

Medicines Management Guidance

Medicines Management Guidance Medicines Management Guidance Status Final Version 1.0 Author Jon Boyd Version date 05/12/2016 Agreed by the following North West London CCGs: Central London West London Hammersmith and Fulham Hounslow

More information

PGDs are permitted for use only by registered health professionals (see enclosed link for full list

PGDs are permitted for use only by registered health professionals (see enclosed link for full list NHS England North - Yorkshire and the Humber Region Protocol for the Development, Authorisation and Use of Patient Group Directions for the National Immunisation Programmes 1. Introduction The preferred

More information

POLICY FOR THE IMPLEMENTATION OF SECTION 132 OF THE MENTAL HEALTH ACT (MHA) 1983 AS AMENDED BY THE MHA 2007:

POLICY FOR THE IMPLEMENTATION OF SECTION 132 OF THE MENTAL HEALTH ACT (MHA) 1983 AS AMENDED BY THE MHA 2007: POLICY FOR THE IMPLEMENTATION OF SECTION 132 OF THE MENTAL HEALTH ACT (MHA) 1983 AS AMENDED BY THE MHA 2007: PROVISION OF INFORMATION TO DETAINED PATIENTS Document Author Written By: Lead for Mental Health

More information

Medicines Management Policy

Medicines Management Policy Medicines Management Policy Name of Policy: Purpose of Policy: Directorate responsible for Policy Name & Title of Author: Medicines Management Policy The Southern HSC Trust recognises that almost all patients

More information

Statement of Guidance: Outsourcing Regulated Entities

Statement of Guidance: Outsourcing Regulated Entities Statement of Guidance: Outsourcing Regulated Entities 1. STATEMENT OF OBJECTIVES 1.1 This Statement of Guidance ( Guidance ) is intended to provide guidance to regulated entities on the establishment of

More information

Medicines Reconciliation: Standard Operating Procedure

Medicines Reconciliation: Standard Operating Procedure Clinical Medicines Reconciliation: Standard Operating Procedure Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation

More information